PL2949361T3 - Steroidy C-19 do leczenia celulitu - Google Patents

Steroidy C-19 do leczenia celulitu

Info

Publication number
PL2949361T3
PL2949361T3 PL15172134T PL15172134T PL2949361T3 PL 2949361 T3 PL2949361 T3 PL 2949361T3 PL 15172134 T PL15172134 T PL 15172134T PL 15172134 T PL15172134 T PL 15172134T PL 2949361 T3 PL2949361 T3 PL 2949361T3
Authority
PL
Poland
Prior art keywords
steroids
treating cellulite
cellulite
treating
Prior art date
Application number
PL15172134T
Other languages
English (en)
Inventor
Martin Windisch
Original Assignee
Athenion Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athenion Ag filed Critical Athenion Ag
Publication of PL2949361T3 publication Critical patent/PL2949361T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/02Suppositories; Bougies; Bases therefor; Ovules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PL15172134T 2007-11-13 2007-11-13 Steroidy C-19 do leczenia celulitu PL2949361T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15172134.7A EP2949361B1 (en) 2007-11-13 2007-11-13 C-19 steroids for treating cellulite
EP07022016.5A EP2060300B1 (en) 2007-11-13 2007-11-13 C-19 steroids for therapeutic uses

Publications (1)

Publication Number Publication Date
PL2949361T3 true PL2949361T3 (pl) 2017-09-29

Family

ID=39183133

Family Applications (4)

Application Number Title Priority Date Filing Date
PL15172134T PL2949361T3 (pl) 2007-11-13 2007-11-13 Steroidy C-19 do leczenia celulitu
PL07022016T PL2060300T3 (pl) 2007-11-13 2007-11-13 Steroidy c-19 do zastosowań terapeutycznych
PL12171940T PL2500062T3 (pl) 2007-11-13 2007-11-13 Steroidy C-19 do określonych zastosowań terapeutycznych
PL12194964T PL2564900T3 (pl) 2007-11-13 2008-11-12 Steroidy C-19 do zastosowań terapeutycznych

Family Applications After (3)

Application Number Title Priority Date Filing Date
PL07022016T PL2060300T3 (pl) 2007-11-13 2007-11-13 Steroidy c-19 do zastosowań terapeutycznych
PL12171940T PL2500062T3 (pl) 2007-11-13 2007-11-13 Steroidy C-19 do określonych zastosowań terapeutycznych
PL12194964T PL2564900T3 (pl) 2007-11-13 2008-11-12 Steroidy C-19 do zastosowań terapeutycznych

Country Status (16)

Country Link
US (1) US10265328B2 (pl)
EP (5) EP2949361B1 (pl)
JP (1) JP6025301B2 (pl)
KR (2) KR20160036100A (pl)
CN (1) CN101854979B (pl)
AU (1) AU2008323199B2 (pl)
CA (1) CA2705533C (pl)
CY (1) CY1116496T1 (pl)
DK (4) DK2500062T3 (pl)
ES (4) ES2547339T3 (pl)
HR (1) HRP20150715T1 (pl)
HU (2) HUE027440T2 (pl)
PL (4) PL2949361T3 (pl)
PT (3) PT2500062E (pl)
SI (1) SI2564900T1 (pl)
WO (1) WO2009062683A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2964323B1 (fr) * 2010-09-08 2012-11-09 Jean Pierre Raynaud Utilisation de la testosterone chez un patient en deficit androgenique et atteint d'un cancer de la prostate
KR20190117803A (ko) * 2011-05-15 2019-10-16 에이세러스 파마슈티칼즈 에스알엘 비내용 테스토스테론 바이오-접착제 겔 제형 및 남성의 성선기능저하증을 치료하기 위한 그의 용도
AU2014252652A1 (en) * 2013-04-10 2015-11-26 Glycobiosciences, Inc. Topical nutraceutical composition
RS56621B1 (sr) * 2014-12-30 2018-03-30 Curadis Gmbh C-19 steroidi za inhibiranje neovaskularizacije
EP3632445A1 (en) 2018-10-04 2020-04-08 Curadis GmbH Combinations with a c-19 steroid for treating cancers
CN112972465B (zh) * 2021-02-22 2022-09-13 复旦大学附属中山医院 一种雄激素受体拮抗剂在制备治疗心血管疾病药物中的应用
KR102554865B1 (ko) 2021-10-05 2023-07-12 경상북도(농업기술원) 친환경 덩굴 절단 파쇄장치

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2762818A (en) 1955-05-26 1956-09-11 Searle & Co 4-hydroxytestosterone and esters thereof
DE3121153A1 (de) * 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung von aromatase-hemmern zur prophylaxe und therapie der prostatahyperplasie"
DE3121152A1 (de) * 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung der kombination eines aromatase-hemmers mit einem antiandrogen zur prophylaxe und therapie der prostatahyperplasie"
JPS62132810A (ja) 1985-12-05 1987-06-16 Shiseido Co Ltd 化粧料
GB8721384D0 (en) 1987-09-11 1987-10-21 Erba Farmitalia 17-substituted andro-sta-1 4-dien-3-one derivatives
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
GB9021546D0 (en) 1990-10-04 1990-11-21 Beecham Group Plc Novel composition
WO1992007586A1 (en) 1990-10-31 1992-05-14 Beecham Group Plc Topical composition with retinoid penetration enhancer
DE4405898A1 (de) 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
US5824326A (en) 1997-06-27 1998-10-20 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Activity enhancement of ferulic acid with dimethyl isosorbride in cosmetic compositions
CA2669753C (en) * 1999-09-30 2012-06-26 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
GB9930839D0 (en) 1999-12-30 2000-02-16 Pharmacia & Upjohn Spa Process for treating gynecomastia
GB0012293D0 (en) 2000-05-23 2000-07-12 Astrazeneca Ab Pharmaceutical combination
US6242436B1 (en) * 2000-06-15 2001-06-05 William Charles Llewellyn Use of 5alpha-androstanediol or 5alpha-androstanedione to increase dihydrotestosterone levels in humans
WO2003026568A2 (en) * 2001-09-21 2003-04-03 Merck & Co., Inc. Androstanes as androgen receptor modulators
US6586417B1 (en) * 2002-04-22 2003-07-01 Nutrisport Pharmacal, Inc. Ester and ether derivatives of 4-hydroxy 4-androstene-3,17-dione and a method for the regulation of athletic function in humans
US20030199487A1 (en) 2002-04-22 2003-10-23 Mr. Vince Paternoster Ester and ether derivatives of 4-hydroxytestosterone and a method for the regulation of athletic function in humans
US20030229063A1 (en) 2002-06-05 2003-12-11 Llewellyn William Charles Use of 4-hydroxytestosterone to lower estrogen levels in humans
JP2006506369A (ja) * 2002-10-15 2006-02-23 ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション メチレン架橋選択的アンドロゲン受容体調節剤及びその使用方法
US20060018937A1 (en) * 2002-10-25 2006-01-26 Foamix Ltd. Steroid kit and foamable composition and uses thereof
EP1689864A2 (en) 2003-10-21 2006-08-16 Dyad Pharmaceutical Corporation Method and compositions for treating 5alpha-reductase type 1 and type 2 dependent conditions
AU2004308260A1 (en) 2003-12-12 2005-07-14 University Of Rochester Non-androgen dependent roles for androgen receptor and non-androgen related inhibitors of androgen receptor
JP2008007404A (ja) * 2004-10-08 2008-01-17 Nippon Kayaku Co Ltd 新規ピリジン誘導体
EP1847541A4 (en) * 2005-02-03 2009-12-30 Takeda Pharmaceutical CONDENSED PYRIMIDINE DERIVATIVE AND USE THEREOF
WO2006084312A1 (en) 2005-02-09 2006-08-17 Acrux Dds Pty Ltd Method of promoting hair growth
JP4755845B2 (ja) 2005-04-28 2011-08-24 共栄化学工業株式会社 テストステロン−5α−リダクターゼ阻害剤及びテストステロン−5α−リダクターゼ阻害剤を含有する化粧料。
EP1854465A1 (en) * 2006-05-12 2007-11-14 Alexander Tobias Teichmann Use of 4,17 beta-dihydroxyandrost-4-ene-3-one for treating cancers
ES2574933T3 (es) * 2007-11-13 2016-06-23 Athenion Ag Esteroides de C-19 para usos cosméticos

Also Published As

Publication number Publication date
KR20100094975A (ko) 2010-08-27
DK2949361T3 (en) 2017-07-03
EP2564900B1 (en) 2015-04-22
EP2564900A1 (en) 2013-03-06
HUE025577T2 (en) 2016-04-28
PT2500062E (pt) 2015-10-12
ES2543047T3 (es) 2015-08-14
US10265328B2 (en) 2019-04-23
PT2564900E (pt) 2015-09-10
ES2547339T3 (es) 2015-10-05
EP2500062A2 (en) 2012-09-19
EP2060300A1 (en) 2009-05-20
CY1116496T1 (el) 2017-03-15
AU2008323199A1 (en) 2009-05-22
PL2060300T3 (pl) 2015-08-31
CN101854979A (zh) 2010-10-06
CA2705533C (en) 2016-02-16
HRP20150715T1 (hr) 2015-08-14
EP2949361B1 (en) 2017-03-22
ES2539800T3 (es) 2015-07-06
DK2564900T3 (en) 2015-07-20
SI2564900T1 (sl) 2015-08-31
US20110263547A1 (en) 2011-10-27
JP2011503130A (ja) 2011-01-27
PT2060300E (pt) 2015-07-17
HK1148704A1 (zh) 2011-09-16
PL2500062T3 (pl) 2015-12-31
AU2008323199B2 (en) 2014-08-28
EP2060300B1 (en) 2015-04-15
EP2949361A1 (en) 2015-12-02
HUE027440T2 (en) 2016-10-28
EP2500062B1 (en) 2015-08-12
EP2500062A3 (en) 2012-11-21
DK2060300T3 (da) 2015-06-22
KR20160036100A (ko) 2016-04-01
PL2564900T3 (pl) 2015-10-30
DK2500062T3 (en) 2015-09-21
JP6025301B2 (ja) 2016-11-16
CN101854979B (zh) 2015-11-25
WO2009062683A1 (en) 2009-05-22
EP2260903A1 (en) 2010-12-15
CA2705533A1 (en) 2009-05-22
ES2628507T3 (es) 2017-08-03

Similar Documents

Publication Publication Date Title
IL257418A (en) Methods for treating addiction
EP2282826A4 (en) PROCESS FOR TREATMENT OF ODOR
PL2310034T3 (pl) Peptydy do leczenia beta-amyloidoz
EP2262366A4 (en) COMPOUNDS AND METHODS FOR TREATING STROGEN RECEPTOR-RELATED DISEASES
GB0722531D0 (en) Control apparatus
EP2134895A4 (en) APPARATUS FOR TREATING CLOTHES
GB0706783D0 (en) Apparatus for deploying endoscope
IL209693A0 (en) Methods for preparing 17 - alkynyl - 7 hydroxy steroids and related compounds
EP2134894A4 (en) CLOTHING TREATMENT UNIT
IL213398A0 (en) Compounds for treating cancer
IL199739A0 (en) Methods for treating psoriasis
TWI350451B (en) Integrated memory control apparatus
EP2327974A4 (en) TISSUE TREATMENT DEVICE
IL238394A0 (en) Cancer treatment method
IL212212A0 (en) Compound useful for treating cellulite
GB0804496D0 (en) Treating cancer
PL2949361T3 (pl) Steroidy C-19 do leczenia celulitu
PL2131841T3 (pl) Sposoby leczenia bólu ostrego
EP2144888A4 (en) METHODS OF TREATING CANCER
GB0702537D0 (en) Treatment for excessive adiposity
SI2349134T1 (sl) Naprava za zdravljenje debelosti
EP2240192A4 (en) TREATMENT OF DERMATOLOGICAL SUFFERING
TWI348698B (en) Method for operating memory
GB0700572D0 (en) Composition for treating dermatological conditions
ZA201000867B (en) Methods for treating dependence